Aquavan NDA Delayed While Guilford Adjusts Dosing In Phase III Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Guilford's suspension of Aquavan Phase III trial enrollment to recalculate dosing levels will delay an NDA filing until the second half of 2006, the firm says